-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LPXTI-641 in Rheumatoid Arthritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LPXTI-641 in Rheumatoid Arthritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LPXTI-641 in Rheumatoid Arthritis Drug Details: LPX-TI641 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LPXTI-641 in Demyelinating Diseases
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LPXTI-641 in Demyelinating Diseases report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LPXTI-641 in Demyelinating Diseases Drug Details: LPX-TI641 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LPXTI-641 in Neuromyelitis Optica (Devic’s Syndrome)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LPXTI-641 in Neuromyelitis Optica (Devic's Syndrome) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LPXTI-641 in Neuromyelitis Optica (Devic's Syndrome) Drug Details: LPX-TI641 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LPXTI-641 in Multiple Sclerosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LPXTI-641 in Multiple Sclerosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LPXTI-641 in Multiple Sclerosis Drug Details: LPX-TI641 is under development for the...
-
Product Insights
Neuromyelitis Optica (Devic’s Syndrome) – Drugs In Development, 2023
Global Markets Direct’s, ‘Neuromyelitis Optica (Devic’s Syndrome) - Drugs In Development, 2023’, provides an overview of the Neuromyelitis Optica (Devic’s Syndrome) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Neuromyelitis Optica (Devic’s Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...